肝癌领域最重要的 21 项临床研究汇总(保持更新)

抽时间将肝癌领域的临床研究做了梳理,总结出了其中最重要的 21 项临床研究。虽然其中大多数是阴性结果,但这些失败的研究跟成功的少数研究一起,塑造了目前肝癌治疗的现状。此外,这些研究中的绝大多数本站都曾经涉及过,如果本站讨论过,链接则直接为站内链接,否则为站外链接。

No. Name Year Treatment Ref
1 SHARP 2008 sorafenib vs placebo Llovet et al., 2008
2 Oriental 2009 sorafenib vs placebo Cheng et al., 2009
3 BRISK-PS 2013 2nd line, brivanib vs placebo Llovet et al., 2013
4 BRISK-FL 2013 brivanib vs sorafenib Johnson et al., 2013
5 2013 sunitinib vs sorafenib Cheng et al., 2013
6 GIDEON 2014 sorafenib, real-world Lencioni et al., 2014
7 EVOLVE-1 2014 2nd line, everolimus vs placebo Zhu et al., 2014
8 STORM 2015 adjuvant settings: sorafenib vs placebo Bruix et al., 2015
9 SEARCH 2015 sorafenib + erlotinib vs sorafenib Zhu et al., 2015b
10 2015 linifanib vs sorafenib Cainap et al., 2015
11 REACH 2015 ramucirumab vs placebo Zhu et al., 2015a
12 BRIDGE 2015 real-world Park et al., 2015
13 RESORCE 2016 2nd line, regorafenib vs placebo Bruix et al., 2016
14 CALGB 80802 (Alliance) 2016 sorafenib + doxorubicin vs  sorafenib Link
15 CheckMate 040 2017 nivolumab (Opdivo) El-Khoueiry et al., 2017
16 SARAH 2017 SIRT w/Y90 vs sorafenib Vilgrain et al., 2017
17 SIRveNIB 2017 SIRT w/Y90 vs sorafenib link
18 CELESTIAL 2017 2nd line, cabozantinib vs control link
19 2018 lenvatinib vs sorafenib Kudo, et al., 2018

20 METIV-HCC 2017 2nd line, tivantinib vs placebo link
21 CheckMate 459 pending nivolumab vs sorafenib link